Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zhaoke Ophthalmology Ltd. ( (HK:6622) ) has shared an announcement.
Zhaoke Ophthalmology Limited announced the approval of its Investigational New Drug application for PAN-90806, an innovative eye drop for treating wet age-related macular degeneration, by China’s National Medical Products Administration. Additionally, the company received marketing authorization for Epinastine HCl eye drops for allergic conjunctivitis. These developments are expected to enhance the company’s market position by offering less invasive treatment options and addressing significant market needs in China, where the wAMD drug market is projected to grow substantially.
The most recent analyst rating on (HK:6622) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Zhaoke Ophthalmology Ltd. stock, see the HK:6622 Stock Forecast page.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a company focused on the ophthalmology industry, specializing in the development and commercialization of eye care products. The company is involved in creating treatments for conditions such as age-related macular degeneration and allergic conjunctivitis, with a market focus on China and potentially global markets.
Average Trading Volume: 1,570,575
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.7B
Find detailed analytics on 6622 stock on TipRanks’ Stock Analysis page.